#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
GLP-1 skin reactions: what two cases show
Two case reports link GLP-1 medicines to unusual skin reactions. Here is what they observed, and why they cannot establish risk or causation.
Tirzepatide vs semaglutide: indirect data
A 2026 analysis compared SURMOUNT-1 with STEP 1. Tirzepatide 10 mg and 15 mg were associated with greater weight reduction, but this was not a new trial.
Incretin injections vs intensified insulin
A 2026 review found lower hypoglycaemia and weight with incretin-based injections versus intensified insulin, but the average HbA1c edge was small.
Semaglutide vs retatrutide: one vs three
Semaglutide hits one receptor and has cardiovascular outcome data. Retatrutide hits three and is still investigational.
Oral semaglutide 25 mg vs the injection
A Novo Nordisk funded indirect comparison put oral semaglutide 25 mg against the 2.4 mg injection. The weight-loss gap was about one percentage point.
GIP receptors and brain dopamine in mice
A 2026 mouse study found GIP receptors in the lateral septum, where GIP and GLP-1 agonists cut electrically evoked dopamine release.
GLP-1 Prescribing Without an Indication
A US records study of 92 million adults found GLP-1 prescribing without a documented indication rose 15-fold, and 35.1% of recipients had a normal BMI.
Semaglutide vs orforglipron: who paid?
A new indirect comparison says oral semaglutide beats orforglipron on weight loss. Five of its eight authors work for Novo Nordisk. Here is what it shows.
Orforglipron vs oral semaglutide in T2D
ACHIEVE-3 put the orforglipron pill head to head with the oral semaglutide pill in type 2 diabetes. Orforglipron won on HbA1c and lost on tolerability.
Semaglutide and wet AMD: signal vs proof
A 2026 study flagged semaglutide among five drugs with raised wet AMD reporting. Here is what that kind of signal can and cannot tell you.
Retatrutide and gut-health claims
A podcast discussion can raise useful questions, but phase 2 retatrutide evidence does not make it an approved general tool for gut health.
Oral Semaglutide and Cognitive Decline Risk
A small elderly-cohort study links oral semaglutide to less cognitive impairment than DPP-4 inhibitors, but a large Alzheimer's trial found no benefit.